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ABSTRACT
Background. Despite the widespread use of antibodies as a research tool, problems
with specificity, lot-to-lot consistency and sensitivity commonly occur and may be
important contributing factors to the ‘replication crisis’ in biomedical research. This
makes the validation of antibodies and accurate reporting of this validation in the
scientific literature extremely important. Therefore, some journals now require authors
to comply with antibody reporting guidelines.
Methods. We used a quasi-experimental approach to assess the effectiveness of such
journal guidelines in improving antibody reporting in the scientific literature. In
a sample of 120 publications, we compared the reporting of antibody validation
and identification information in two journals with guidelines (Nature and the
Journal of Comparative Neurology) with two journals without guidelines (Science and
Neuroscience), before and after the introduction of these guidelines.
Results. Our results suggest that the implementation of antibody reporting guidelines
might have some influence on the reporting of antibody validation information. The
percentage of validated antibodies per article slightly increased from 39% to 57%
in journals with guidelines, whereas this percentage decreased from 23% to 14% in
journals without guidelines. Furthermore, the reporting of validation information of
all primary antibodies increased by 23 percentage points in the journals with guidelines
(OR = 2.80, 95% CI = 0.96-INF; adjusted p = 1, one-tailed), compared to a decrease
of 13 percentage points in journals without guidelines. Fortunately, the guidelines seem
to be more effective in improving the reporting of antibody identification information.
The reporting of identification information of all primary antibodies used in a study
increased by 58 percentage points (OR = 17.8, 95% CI = 4.8-INF; adjusted p =
0.0003, one-tailed) in journals with guidelines. This percentage also slightly increased in
journals without guidelines (by 18 percentage points), suggesting an overall increased
awareness of the importance of antibody identifiability. Moreover, this suggests that
reporting guidelines mostly have an influence on the reporting of information that is
relatively easy to provide. A small increase in the reporting of validation by referencing
the scientific literature or the manufacturer’s data also indicates this.
Conclusion. Combined with the results of previous studies on journal guidelines, our
study suggests that the effect of journal antibody guidelines on validation practices by
themselves may be limited, since they mostly seem to improve antibody identification
instead of actual experimental validation. These guidelines, therefore, may require ad-
ditional measures to ensure effective implementation. However, due to the explorative
nature of our study and our small sample size, we must remain cautious towards other
factors that might have played a role in the observed change in antibody reporting
behaviour.
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INTRODUCTION
Antibodies are veritable workhorses in biomedical research. Used to label specific molecules
or antigens (generally proteins), they allow researchers to map biomolecular processes in
the cell. Through techniques such as western blotting (WB), immunohistochemistry, or
ELISA, the use of antibodies has become widespread in biological research.
However, binding antibodies to antigens is intricate and full of complications. Antibodies
may lack specificity and their affinity for specific antigens may vary. Furthermore, their
affinity may vary with experimental conditions (Baker, 2015b), for example when pH levels
or reagents denature proteins, altering protein folding and thereby the epitopes to which
antibodies bind. Among tens of thousands of antibodies on offer (largely from commercial
suppliers), researchers need to identify precisely which antibodies are most suitable for
their antigens of interest, under their precise experimental circumstances. To aid this
selection, extensive support tools have been developed, such as the Antibodypedia, or the
Antibodyregistry, which support the identification of antibodies with research resource
IDs (RRIDs) (Bandrowski et al., 2016).
Nevertheless, even with the help of such resources, the practice of antibody use remains
complex. While researchers may identify the correct antibody for their specific research
purposes in principle, verifying that the correct antibodies are used in practice is a different
matter. Antibodies may vary from batch to batch, suppliers may not always be able to
guarantee relevant quality standards, or earlier mistakes may be obfuscated by relying on
locally established routines, such as habits, experimental skills, and techniques passed
on in a laboratory. If identification and validation information about antibodies is
not reported accurately, the possibility of experimental replication is jeopardised, and
subsequent research may be built on errors. In turn, this may lead to wasted research,
missed opportunities for medical innovation, or even patient safety risks. Taken together,
the costs involved may be considerable. In fact, some commentators suggest problems with
antibody validation, or lack of validation information, may be an important contributing
factor to the ‘replication crisis’ in biomedical research (Freedman, Cockburn & Simcoe,
2015).
For over a decade, various researchers have expressed concerns about insufficient
antibody validation in biomedical research (Baker, 2015a; Bordeaux et al., 2010; Saper
& Sawchenko, 2003). The challenges are considerable. One study validating over 5,000
commercial antibodies for the Human Protein Atlas (HPA) showed that half of these
antibodies were not suitable for the specific immunohistochemistry application in theHPA.
The researchers concluded that every application of antibodies requires application-specific
validation (Berglund et al., 2008).
Advocates of tighter validation have suggested techniques and principles to ensure
correct antibodies are used and to improve reporting of antibody validation information
in publications, although there is no universal standard as yet (GBSI, 2016). At the very
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least, these advocates suggest that researchers should report information that establishes
the identity of antibodies used, via reference to RRIDs or supplier identifiers, including
catalogue and batch number (Vasilevsky et al., 2013). While many researchers rely on the
literature to establish application-specific validity of antibodies, actual validation testing
avoids repetition of older mistakes. This testing should verify not just the identity, avoiding
supply-line errors (such as misidentification during personal exchange, or transport via
suppliers), but also the antibody’s specificity for the target protein and sensitivity in the
specific application. Relatively simple checks include staining a western blot to check
whether antibodies recognise antigens of the correct molecular weight, omitting the
primary antiserum, and performing pre-adsorption controls (Saper & Sawchenko, 2003).
While these methods might be useful as a first indicator of an antibody’s specificity,
they are not very stringent, and antibodies might still be found to be nonspecific upon
more thorough validation (Andersson et al., 2017; Bordeaux et al., 2010; Hewitt et al., 2014;
O’Hurley et al., 2014).
The International Working Group of Antibody Validation (IWGAV) proposed a very
stringent validation procedure in 2016, with five ‘pillars’ for application-specific validation.
These include genetic strategies (testing the antibody in conditions when the protein is not
expressed), orthogonal strategies (comparing results for varying amounts of target protein
identified by other means), independent antibody strategies (comparing results with
alternative antibodies), expression of tagged proteins (using affinity tags or fluorescent
proteins), and immunocapture followed by mass spectrometry. The IWGAV advises
researchers to carry out at least one of these five methods in order to validate whether
an antibody is truly specific to the application at hand. Furthermore, the IWGAV advises
suppliers to also use at least one of these five pillars for validation, including validation for
each new batch of antibodies, and to provide specific information on optimal use (Uhlén
et al., 2016).
Several initiatives encourage researchers to improve antibody validation. Apart from calls
to action in editorials, the development of databases, and improved validation by suppliers,
some journals have also stepped up to the plate. The first and most vocal initiative was
taken by the Journal of Comparative Neurology (JCN ), introducing explicit requirements
for antibody validation in its author instructions in 2003 (Saper, 2005; Saper & Sawchenko,
2003). Several journals followed suit and now require various levels of antibody validation
information: some require only identification information; others require documentation
or actual experimental proof of application-specific validity (Steve et al., 2018; Gore, 2013;
Nature, 2013).
In essence, these journal initiatives constitute rule-based or ‘regulatory’ policy,
attempting to change researchers’ behaviour through regulation. These vary from
insistent but voluntary guidelines, through checklists that attempt to ‘nudge’ authors
into compliance (Babic et al., 2019), or actual rules at penalty of editorial rejection. In
policy sciences, the track record of rule-based behaviour modification is mixed, at best.
Rules require policing, which is expensive, and rules tend to fail if they lack community
support, for example if they are perceived as meaningless or ineffectual. In matters of
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research integrity, rules that blatantly diverge from actual practice have been shown to
induce cynicism among researchers, decreasing willingness to comply (Clair, 2015).
Although journals have long been considered powerful ‘gatekeepers of science’ (Crane,
1967), and journals are generally expected to maintain standards in research communities,
their power to do so is not absolute. Journals are also dependent on research communities
for submitted articles and willingness of reviewer cooperation, compounded by the hard
economics of publishing in which volume is often the backbone of the business model
(Larivière, Haustein & Mongeon, 2015). Hence, the possibility of journals to raise standards
may be limited by what the research community is willing to maintain.
From this perspective, it is interesting to investigate the effect of journal antibody
guidelines on the presence and quality of reported validation information. For these
purposes, we chose to compare antibody validation information in journals with guidelines
and in equivalent journals without guidelines, i.e., a control group. Our hypothesis was that
antibody validation information would improve in the journals that introduced antibody
validation guidelines.
Before we turn to the details of our research method, we want to discuss some key
methodological assumptions in validation testing, which touch upon quite fundamental
issues of philosophy of science. First, we want to make an important distinction between
antibody reliability and antibody validity. Antibodies may reliably produce the same
results if experimental conditions are reproduced exactly, but if these conditions are
based on misconceptions, they could simply reliably reproduce systematic error. A striking
example of how the reproduction of errormight lead research astray, comes from the recent
evaluation of antibodies against oestrogen receptor beta in breast cancer research.Andersson
et al. (2017) discovered that the antibodies most cited in the literature had systematically
stained the wrong proteins in tissue samples and that the target protein was not even present
in breast cancer tissue, affecting two decades of research. Hence, validation would ideally
constitute the experimental confirmation under different conditions, providing more
robust replication, rather than identical reproduction, as recent philosophy of science has
argued (Leonelli, 2018). In the case of antibodies, the principles of the ‘five pillars’ offer
such variation in experimental conditions. In contrast, strictly speaking, reference to exact
reproduction of antibodies as used in the literature only constitutes proof of reliability,
although it is frequently presented as proof of validity.
Second, while exact reproduction can be considered important evidence for antibody
reliability in specific applications, in the practice of antibody research this evidence is
not absolute: it always remains possible to question whether the reproduced experiment
was indeed identical or performed equally expertly. Lack of exact reproduction raises the
possibility that the repeat experiment failed to reproduce the exact original conditions
and materials, or lacked some quality in the performer, such as particular experimental
skills (Collins, 1985). In the case of antibodies, this is particularly pertinent in the case of
polyclonal antibody batches that have run out, for example as source animal populations
are terminated. Moreover, whether an application of antibodies constitutes an exact
reproduction may be difficult to establish based on concise information provided in
databases or even publications. Lack of reproduction therefore does not automatically
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Figure 1 Overview of the research strategy. Samples of 15 articles were taken from journals that did
(1 and 2) and that did not (3 and 4) introduce antibody reporting guidelines. These samples were taken
from a timeframe before (August 2002–August 2003) and after (June 2017–June 2018) the introduction of
guidelines by journal 1 and 2. An increase in antibody validation reporting was expected between the sam-
ples connected with a black arrow, while no difference was expected between the samples connected with a
dashed grey arrow.
Full-size DOI: 10.7717/peerj.9300/fig-1
disqualify the reliability of the original experiment and exact reproduction may be hard to
assess in practice.
In scoring the quality of validation information, we should therefore pay attention
to information that establishes the identity of antibodies, to evidence for antibodies’
reliability in the specific intended purposes, and to evidence that experimentally confirms
the antibodies’ adequacy to identify the intended antigens with precision. While only
the latter constitutes proper validation, information about identity and reliability is a
precondition of such higher levels of validation.
MATERIALS & METHODS
Research strategy
In this exploratory study, we used a quasi-experimental study design to assess whether
journal antibody validation guidelines can improve antibody validation reporting (see
Fig. 1). We selected two journals that had adopted such guidelines and two journals with
a comparable impact factor and research area, but without guidelines. We took random
samples of 15 articles from each journal from a one-year timeframe before and after the
two journals implemented antibody reporting guidelines. We used the study performed
by Han et al. (2017) as an indication of the sample size and did not perform a power
calculation beforehand. Since the first selected journal with guidelines created awareness of
the antibody problem in August 2003, the ‘before guidelines’ samples consisted of articles
that were published between August 2002 and August 2003. The ‘after guidelines’ samples
consisted of articles that were published between June 2017 and June 2018, because the
second journal with guidelines implemented its most stringent guidelines in June 2017. We
then used an antibody validation coding table to assess the antibody validation information
provided by each of the articles. We evaluated a total of 120 articles.
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1Editorial policies at JCN have recently
changed. The Antibody Characterization
section in force at the time of this study is
no longer a requirement.
Journal selection
Intervention group
The Journal of Comparative Neurology (JCN) and Nature were selected as the two journals
with antibody validation guidelines. With regard to antibodies, JCN requires authors to
add an ‘Antibody Characterization’ section to the methods section of a paper.1 This section
should include complete identification information of the used antibodies and proof of
their validity. Authors can report their own validation or describe and cite evidence from
the literature. The guidelines further specify that just a casual reference to a supplier’s
data sheet does not count as reliable evidence of specificity (information from Author
Guidelines section of website Journal Comparative Neurology, retrieved on 04-05-2018).
When authors want to submit a manuscript to JCN, they need to check a box that states
that their publication provides full (validation) information on all antibodies used (article
submission process tested on 09-05-2018).
The journal Nature has been asking authors in the life sciences to fill out a reporting
checklist since May 2013. Since June 2017, this checklist has been replaced by a reporting
summary to be published as supplementary information alongside the article. While the
previous checklist and current reporting summary are not uniquely intended for antibodies,
these documents do ask for exhaustive identification and validation information on
antibodies. Furthermore, filling out this reporting summary is a requirement for publication
in Nature. The form needs to be uploaded at submission to prevent manuscript processing
delays (article submission process tested on 09-05-2018). A more elaborate explanation of
these journals’ guidelines can be found in Article S1.
Control group
The InCites Journal Citations Reports function of Web of Science (WoS) was used to find
journals comparable to JCN and Nature. Comparable journals were chosen by selecting
the first journal with a similar impact factor from the Cited Journal Data. Journals in this
network are considered similar because they fit in the same research area and are part of
the same citation network.
In the case of JCN, the most similar journal is Neuroscience with a similar impact
factor and research category of neurosciences. The journal Neuroscience does not have
antibody validation guidelines. No specific information about antibodies can be found in
the author guidelines for article submission on Neuroscience’s website. The website does
provide information on resource materials in general. The source of all materials used
should be provided and the location of each supplier should be provided on first use in
the text (information from Guide for Authors section on website Neuroscience, retrieved
04-05-2018). However, at submission, authors are not asked to provide information on
the materials they used or on antibodies specifically (article submission process tested on
09-05-2018).
A comparable journal to Nature is Science, as they are both multidisciplinary journals
with similar impact factors. Using the samemethod as before, Science is also the first journal
with a comparable impact factor in the list of cited journals of Nature. While Science does
state that antibodies should be validated, this instruction is cursory and hard to find. It is
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written between brackets on the ‘Editorial Policies’ page of the Science website, rather than
in author instructions. There is no further elaboration on what validation should consist
of. Furthermore, the manuscript submission process of Science never asks authors for
validation information onmaterials that are used in a study and never mentions antibodies.
Hence, Science can be regarded as having very marginal, to no guidelines on antibody
reporting when compared to Nature (information from Information for Authors/Editorial
Policies section on website Science, retrieved 04-05-2018; article submission process tested
on 09-05-2018).
Article selection
WoS was used to search for articles published between 2002 and 2003 or between 2017
and 2018 in each of the four journals. These lists of articles were then randomly sorted
by assigning them a random number and sorting these numbers from smallest to largest.
The first 15 articles in these lists in the time span of August 2002–August 2003 and June
2017–June 2018 (according to the WoS publication date) that contained antibodies as a
resource material were then selected for assessment, selecting a total of 120 articles. Using
antibodies as a resource material means that they are used as a tool in a biological method
such as western blotting or immunohistochemistry. Antibodies can also themselves be the
subject of scientific research. In this case the article was only included in the sample if
antibodies were additionally used as a resource material. To determine if an antibody was
used in a study, first the title of the article was used to determine if the article was published
in a field that could use antibodies (e.g., life sciences and not physics). Next, the full text
of the article was visually screened and screened for the word ‘anti’ to see if antibodies as
a resource material were mentioned in the article. If this word did not occur in the full
text in relation to antibodies, it was assumed that no antibodies had been used. In case of




All articles and their supplementary information were then scanned for antibody
(validation) information, and this information was collected in a coding table. The coding
table was carefully constructed by evaluating the literature for different antibody validation
methods, by consulting researchers working with antibodies, and by checking the table on
a set of testing articles.
Information was collected per article, not per antibody. If multiple antibodies were
validated by multiple methods of validation, all methods were noted for this paper. In case
of doubt about the answer to a question, the decision was always made to rule in favour
of the article. For example, the highest number of validated antibodies would be written
down in case of doubt about how many antibodies were validated.
The coding table consisted mostly of ‘yes’ and ‘no’ questions such as: ‘are all primary
antibodies validated?’ or ‘is validation carried out by positive control?’ When a particular
question was not relevant for the evaluated article (for example, the questions about type
of validation when no antibodies were validated), this question was evaluated as ‘not
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Figure 2 Example of explicit antibody validation. To test the specificity of the antibody, a comparison
was made between the western blots provided by the supplier of the antibody and western blots carried
out by the authors of the paper. According to the supplier, two bands should be observed: one between 25
and 37 kDa and one between 50 and 75 kDa. According to the authors, the additional band at>250 kDa is
likely caused by six connexin protein subunits that form a connexin hemi-channel. The authors explicitly
mention antibody validation as the purpose of this experiment: ‘‘We tested the antibody’s specificity using a
western blot of Gulf toadfish whole brain homogenates.’’ Figure from Rosner et al. (2018).
Full-size DOI: 10.7717/peerj.9300/fig-2
applicable’. When it was impossible to answer a question for a certain article, this question
was coded ‘unclear’. The answer ‘unclear’ was classified as missing in data analysis.
We wanted to know the percentage of articles that report validation or information on
all primary antibodies from the sample of all articles that use antibodies. Therefore, for
the questions ‘are all primary antibodies validated?’ and ‘is the basic information of all
primary antibodies complete?’, the answer ‘not applicable’ was coded as ‘no’ to calculate
the percentage of articles that contain this information in all articles with antibodies. For all
other questions about validation type, the answer ‘not applicable’ was classified as missing.
Wemade this choice because we wanted to know the prevalence of these validation types in
articles with validated antibodies, instead of their prevalence in all articles using antibodies.
A full overview of the coding protocol, the questions in the coding table and the different
antibody validation methods is provided in Article S2.
Implicit and explicit validation
Because we assessed antibody validation information by reading the publication, our coding
made no distinction between explicit or purposeful validation and implicit or ‘accidental’
validation, as the intention to validate cannot always be inferred from the text. Whether
explicitly presented as validation or not, in both cases the antibody (and thus the article it
was used in) was coded as validated. However, for the interpretation of our findings, it is
important to understand this distinction between implicit and explicit validation.
Explicit validation means that the article provides information with the explicit purpose
to attest antibody validity. In this case, experiments are presented with the purpose of
validating the antibody, and/or the words antibody validation are explicitly mentioned. An
example from one of the evaluated articles would be the use of western blot with molecular
weight markers to validate the antibody (see Fig. 2).
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Figure 3 Example of implicit antibody validation. Atg7 defective cells were generated by inhibiting gene
expression of the Atg7 gene with RNA interference. The cells in which Atg7 was silenced show no stain-
ing with anti-ATG7, while wild type cells do. This type of validation was marked as validation by negative
control (RNA interference) and by genetic strategies of the five pillars. From Abu-Remaileh et al. (2017).
Reprinted with permission from AAAS.
Full-size DOI: 10.7717/peerj.9300/fig-3
Implicit validation here means that from reading the article, claims about the validity of
the antibody can be made, but no experiments have specifically been reported to establish
the validity of the antibody. The words ‘antibody validation’ are not mentioned. An
example from one of the evaluated articles would be the use of RNA interference as an
antibody validation method (see Fig. 3).
Methodological reliability
All 120 articles were evaluated by one of us (Joyce Hoek). An independent rater (Wytske
Hepkema) then assessed a randomly selected sample of these articles to determine the
interrater reliability. This sample consisted of 2 articles for each journal and time frame,
resulting in 16 articles or 13% of the total sample. Since Wytske Hepkema only analysed a
small percentage of the total sample, we only used her answers to estimate the interrater
reliability, and we used the answers of Joyce Hoek for data analysis.
The percentage of agreement between both raters (Joyce Hoek and Wytske Hepkema)
was calculated using the agree function of the irr package (Gamer et al., 2012) in R. For
nominal variables, Cohen’s kappa was calculated using the cohen.kappa function of the
psych package (Revelle & Revelle, 2015) in R. For continuous variables, the intra-class
correlation coefficient (ICC) was calculated using the icc function of the irr package
in R. ICC estimates were calculated based on a single-measures, consistency, two-way
mixed-effects model. Missing values were not taken into account in the calculation of
kappa or the ICC. Cohen’s kappa was indeterminate in some cases because one or both
raters answered ‘yes’ or ‘no’ for all evaluated articles. This is indicated by IND in the table.
Table 1 shows the percentage agreement and Cohen’s kappa or intra-class correlation
coefficient.
The agreement between raters varied considerably between the different questions, from
a kappa of 1 to a worse than chance kappa of −0.20. Antibody validation information is
often not explicitly reported, as opposed to antibody identification information, which also
had a higher interrater agreement. The low agreement on antibody validation questions
thus illustrates the current problem of antibody validation reporting: it is very difficult for
a reader to assess the validity of antibodies used in paper and therefore assess the validity
of the performed experiments. A more standardized way of reporting could improve this.
The large disagreement indicates that it is difficult to establish the validity of antibodies
from reading the publication when antibody validation is not explicitly mentioned. The
disagreement between the two raters when it comes to the categories ‘validation carried out
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Basic information all primary antibodies complete? 100% 1.00 1.00–1.00 16
Any validation information present (at least one antibody)? 75% 0.50 0.13–0.87 16
All primary antibodies validated? 94% IND / 16
If validated:
Reference to validation by antibody supplier? 100% IND / 8
Reference to validation in the literature? 88% 0.75 0.31–1.00 8
Reference to validation information in database? 100% IND / 8
Antibody validation carried out by authors of article? 63% −0.20 −0.49–0.088 8
If carried out by authors, which method?
Molecular weight similar to target (in WB)? 83% 0.57 −0.12–1.00 6
Spatial localization? 100% 1.00 1.00–1.00 6
Pre-adsorption/blocking peptide? 100% 1.00 1.00–1.00 6
Using secondary antibody without primary? 100% IND / 6
One of the five pillars? 100% 1.00 1.00–1.00 6
Positive control? 67% 0.33 −0.23–0.90 6
Negative control? 67% IND / 6
Other validation method? 50% 0.00 −0.75–0.75 6
Question ICC 95%CI N
How many antibodies were used? 0.995 0.986–0.998 15
How many antibodies were validated? 0.684 0.263–0.886 14
Percentage of validated antibodies? 0.663 0.226–0.878 14
by the authors of the paper’, ‘negative and positive control’ and ‘other types of validation’
illustrates this. These types of validation are often consequential to the methods used in
an experiment. For example, antibodies are used to validate the silencing of a gene, and, at
the same time, the silencing of this gene can be seen as a method to validate the antibody.
This is a type of circular reasoning that only holds if either the antibody or the silencing
has proven to be valid by other methods. Therefore, it is difficult to judge if the experiment
validates the antibody or not. Because of the low agreement on these questions, they were
not taken into further consideration during data analysis.
On the other hand, the more explicit types of validation are easier to recognize and
to judge by readers of the paper. This is illustrated by the high percentage of agreement
between both raters and kappa value on the categories ‘validation by reference to supplier,
the literature, or a database’, ‘molecular weight similar to target’, ‘spatial localization’,
‘pre-adsorption’ and ‘secondary antibody without primary’.
Data analysis
We compared the reporting of antibody validation information between the samples of
journals with and without guidelines and between the samples of August 2002–August
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2003 and June 2017–June 2018. We expected the proportion of articles reporting validation
to be higher in 2017 than in 2003 in journals that implemented guidelines. Furthermore,
the proportion of validation was expected to be larger in 2017 in the samples of journals
that implemented guidelines compared to journals that did not implement guidelines. We
measured the difference in validation reporting by comparing the percentage of validated
antibodies per article and the proportion of articles reporting any validation information.
We also decided to look at the proportion of articles reporting complete identification or
validation information on all primary antibodies as a more robust measure of validation
rigour.
For the comparisons of proportions, one-tailed p-values were calculated, since these
hypotheses are directional. When comparing the samples of journals without guidelines
between 2003 and 2017, no increase in proportion was expected. Likewise, the samples of
similar journals with and without guidelines taken at baseline in 2003 were not expected
to be different. For this reason, two-tailed p-values were calculated in these cases. Because
of the small sample size, we used Fisher’s exact test (fisher.test in R) to compare the two
proportions (instead of the chi-square or z-test for two proportions). This function uses the
conditional Maximum Likelihood Estimate as an estimate of the odds ratio. For one-tailed
tests, the odds ratio goes to infinity. This is indicated by INF in the text. To account for
multiple comparisons, we used the Holm-Bonferroni correction (p.adjust in R) to adjust
all calculated p-values. Data analysis was carried out using R version 3.3.3.
In line with recent debate about the value of p-values (Wasserstein, Schirm & Lazar,
2019) and because of the exploratory nature of our study, we decided to not only look
at statistically significant (p < 0.05) results, but also take into account meaningful but
non-significant differences. To us, a meaningful difference is a substantial increase in
proportion of validated articles, accompanied by a large odds ratio. We think these
differences are interesting and might be good targets to further investigate if this study
were to be replicated.
We provide our data and R code in Data S1 and S2 and Article S3. Our data can also be
found at https://doi.org/10.17026/dans-xhk-74m4.
RESULTS
Percentage of validated antibodies per article
For each evaluated article, the percentage of validated antibodies per article was calculated
from the total number of antibodies used and the number of validated antibodies. An
overview of these numbers can be found in Table S1.
Figure 4 provides a descriptive overview of the percentages of validated antibodies in
each evaluated article as well as the mean percentage per journal. This figure shows that
the mean percentage of antibodies that have been validated per article for each journal
slightly increased in both journals with guidelines (JCN and Nature) between 2003 and
2017. Combined, these journals increased from an average of 39% to 57% of validated
antibodies per article. This percentage decreased in the journals that did not introduce
reporting guidelines. These journals went from an average of 23% to 14% of validated
antibodies per article.
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Figure 4 Change in percentage of validated antibodies per article before (2003) and after (2017) two
of the journals (JCN andNature) implemented antibody reporting guidelines. Grey dots represent the
percentage of validated antibodies per article, red bars indicate the mean percentage of validated antibod-
ies per article for each journal. Sample size: JCN 2003 n= 15, 2017 n= 14; Neuroscience 2003 n= 14, 2017
n= 15; Nature 2003 n= 15, 2017 n= 14; Science 2003 n= 15, 2017 n= 15.
Full-size DOI: 10.7717/peerj.9300/fig-4
Furthermore, there is a difference in reporting between similar journals with and
without guidelines. This difference in percentage was already present before JCN and
Nature introduced guidelines, but it increased after the introduction of these guidelines. The
difference in average percentage of validated antibodies between JCN andNeuroscience was
20 percentage points before the introduction of guidelines and increased to 49 percentage
points after the introduction of guidelines by JCN. Between Nature and Science, the
difference in average percentage was 12 percentage points, which increased to a difference
of 38 percentage points after the introduction of guidelines by Nature.
Validation of at least one antibody
Next, wemade comparisons about antibody validation at the article level. Instead of looking
at the percentage of validated antibodies per article, we now compared the percentage of
articles that reported the validation of at least one antibody (see Tables S2 and S3). The
reporting of validation improved slightly, but insignificantly, in the journals that had
introduced guidelines. In addition, after the introduction of guidelines, 90% of the articles
that use antibodies in journals with guidelines reported validation of at least one antibody
compared to 53% of articles in journals without guidelines (OR= 7.6, 95% CI= 2.11-INF;
adjusted p= .09, one-tailed). However, since it might be quite simple to implicitly validate
at least one antibody per article, we also chose to compare the percentage of articles
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Figure 5 Change in percentage of articles that reported validation information on all primary anti-
bodies used in the study before (2003) and after (2017) two of the journals (JCN andNature) imple-
mented antibody reporting guidelines. Sample size: with guidelines 2003 n = 30, 2017 n = 28; without
guidelines 2003 n= 30, 2017 n= 30, total 2003 n= 60, 2017 n= 58, JCN 2003 n= 15, 2017 n= 14; Neu-
roscience 2003 n= 15, 2017 n= 15; Nature 2003 n= 15, 2017 n= 14; Science 2003 n= 15, 2017 n= 15. P-
values (one-tailed) were determined with Fisher’s exact test and adjusted using the Holm-Bonferroni cor-
rection.
Full-size DOI: 10.7717/peerj.9300/fig-5
reporting antibody (validation) information for all primary antibodies that they used as a
more robust measure of antibody reporting quality.
Validation of all primary antibodies
First, we compared the percentage of articles that report validation information on all
the primary antibodies used per study. This percentage increased between 2003 and 2017
in both journals (JCN + Nature) that implemented reporting guidelines (see Fig. 5 and
Tables S4 and S5). On average, this percentage increased by 23 percentage points in the
journals that had implemented guidelines (OR = 2.80, 95% CI 0.96-INF; adjusted p =
1, one-tailed). In contrast, the percentage of articles with validation information on all
primary antibodies decreased in both journals without guidelines (Science +Neuroscience).
Furthermore, there was no meaningful increase in the total sample (18% to 22%, OR =
1.28, 95% CI = 0.48–3.52; adjusted p = 1, two-tailed).
At the journal level, there was an increase of 24 percentage points (OR = 2.61, 95% CI
= 0.60-INF, adjusted p= 1, one-tailed) in articles that reported validation information on
all primary antibodies in JCN and an increase of 22 percentage points in Nature (OR =
5.3, 95% CI = 0.59-INF; adjusted p = 1, one-tailed).
By comparing the journals with guidelines to the journals without guidelines, we can see
that the difference in reporting between these similar journals in our sample substantially
increased after the introduction of guidelines. After June 2017, 46% of the articles in
journals that did implement guidelines (JCN + Nature) reported validation of all primary
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antibodies after the introduction of guidelines, compared to 0% in journals that did not
implement guidelines (Neuroscience + Science), a difference of 46 percentage points (OR=
INF, 95% CI = 6.5-INF; adjusted p= .0007, one-tailed). While a difference in percentage
was already present before the introduction of guidelines in 2003, this difference was much
smaller (10 percentage points, OR= 1.96, 95% CI= 0.43–10.3; adjusted p= 1, two-tailed).
At the journal level, there was a large difference of 64 percentage points (OR = INF,
95% CI = 5.1-INF, adjusted p= .01, one-tailed) in validation reporting between the
journals JCN and Neuroscience after June 2017. Between Nature and Science there was a
difference in reporting of 29 percentage points (OR= INF, 95% CI= 1.09-INF; adjusted p
= 1, one-tailed) after Nature had introduced guidelines, a difference that was not present
before.
Identification of all primary antibodies
In addition to looking at antibody validation, we also evaluated how well antibody
identification information was reported for all primary antibodies used in a study.
Antibodies are considered identifiable if enough information is provided in the publication
for readers to be able to track down the antibody and obtain it themselves. In order to do
so, either an RRID or the name, supplier and catalogue number of a commercial antibody
needs to be reported. For non-commercial antibodies either an RRID or the host-animal
and immunogen used needs to be reported. Figure 6 and Tables S6 and S7 show the
percentage of articles that reports identification information on all primary antibodies that
were used in the article.
The percentage of articles that reported identification information on all primary
antibodies increased considerably between 2003 and 2017 in journals that implemented
antibody guidelines. Overall, the percentage of articles that reported identification
information on all primary antibodies increased with 58 percentage points from 10%
to 68% (OR = 17.8 95% CI = 4.8-INF; adjusted p= .0003, one-tailed) in journals with
guidelines (JCN + Nature). Of the separate journals, JCN showed the most improvement
in reporting. After the implementation of guidelines, its percentage increased from 20%
to 93% of articles that use antibodies (OR = 45.2, 95% CI = 5.5-INF; adjusted p= .003,
one-tailed). In the journals Neuroscience and Science this percentage also increased, but
the increase was much smaller than in the journals with guidelines. Overall, the percentage
of articles reporting identification information on all primary antibodies increased with
18 percentage points from 10% to 28% (OR = 3.36, 95% CI = 0.70–22.1; adjusted p
= 1, two-tailed) in journals without guidelines (Neuroscience + Science). Apart from
that, the overall reporting of identification information improved over time. For all
journals combined this percentage increased by 37 percentage points (OR = 7.9, 95% CI
= 2.81–26.3; adjusted p= .0005, two-tailed). This suggests that other factors such as an
increase in awareness, the availability of identifying information, or a changing view on
the importance of antibody reporting by the scientific community might also play a role in
how well antibody identification information is reported.
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Figure 6 Change in percentage of articles that reported identification information on all primary an-
tibodies used in the study before (2003) and after (2017) two of the journals (JCN andNature) imple-
mented antibody reporting guidelines. Sample size: with guidelines 2003 n = 30, 2017 n = 28; without
guidelines 2003 n = 30, 2017 n = 29; total all journals 2003 n = 60, 2017 n = 57; JCN 2003 n = 15, 2017
n = 15; Neuroscience 2003 n = 15, 2017 n = 15; Nature 2003 n = 15, 2017 n = 13; Science 2003 n = 15,
2017 n = 14. P-values were determined with Fisher’s exact test and adjusted using the Holm-Bonferroni
correction. 1two-tailed p-values, other p-values are one-tailed.
Full-size DOI: 10.7717/peerj.9300/fig-6
Change in type of validation
If an article reported validation of at least one antibody, the types of validation that were
carried out in the article were further specified. An article can contain multiple types of
antibody validation, since one antibody can be validated in multiple ways, or multiple
antibodies can be validated by different methods. First, a distinction was made between
validation by the authors of the paper themselves and validation by means of a reference
to the literature, to the information of the supplier, or to validation information in a
database. Validation by the authors implies an experimental check in the laboratory and
involves material verification, while the other forms rely on documentation. Reference
to the supplier implies a reliance on supplier information about validity, reference to the
literature implies a documentation of similar use of these antibodies by other researchers,
which is also possible via reference to a database.
Example of validation by the authors of an evaluated paper:
• Independent antibody strategies of five pillars. ‘‘Our immunostaining in the mouse
embryo cerebellum produced a similar labeling pattern as the other FoxP2 antibody’’
(Vibulyaseck et al., 2017).
Examples of validation by reference to a third party from the evaluated articles:
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• Reference to supplier. ‘‘The rabbit polyclonal anti - FoxP2 antibody (AP5753b, Abgent,
San Diego, California, CA, USA) produced a single major band of 80 kDa in the mouse
heart tissue lysates in the manufacturer’s western blot analysis.’’ (Vibulyaseck et al., 2017).
• Reference to the literature. ‘‘The goat polyclonal anti - EphA4 antibody (AF641, R&D
Systems, Minneapolis, MN, USA) recognized a single band of 110 kDa in HEK293 cell
lysate transfected with the EphA4 gene by western blot (Hashimoto et al., 2012). Its im-
munohistochemical reactivity has been eliminated by preabsorption with the recombinant
EphA4 protein (Rosas et al., 2011)’’ (Vibulyaseck et al., 2017).
Figure 7 and Tables S8 and S9 show the changes in the prevalence of these types of
validation before and after the introduction of guidelines in articles that contain at least
one validated antibody. The percentage of articles that use validation by the authors seems
extremely high. It went from 87% to 85% in journals without guidelines and from 94% to
94% in journals with guidelines between 2003 and 2017. However, these percentages might
be misleading. These high percentages were often caused by a small number of validated
antibodies per article, which is explained by our methodology of evaluating validation
per article instead of per antibody. Moreover, this method of validation is often implicitly
carried out as a consequence of the experimental method being used. Since the reliability
of the rating of this category is questionable (κ = −0.20), we did not perform further
statistical analysis on this category.
Both the use of the validation methods ‘reference to the literature’ and ‘reference to
the antibody supplier’ increased in journals with guidelines (JCN + Nature) after the
introduction of these guidelines. These methods increased by 24 percentage points (OR
= 2.62, 95% CI = 0.86-INF; adjusted p = 1, one-tailed) and 27 percentage points (OR =
INF, 95% CI = 1.96-INF; adjusted p = 0.4, one-tailed) respectively.
Before guidelines were installed, there was a small difference in the prevalence of these
validation types between journals with and without guidelines. This difference increased
after the introduction of guidelines. Before the introduction of guidelines, there was a
difference of 13 percentage points (OR = 1.99, 95% CI = 0.36–14.4; adjusted p = 1,
two-tailed) in validation by reference to the literature between journals with and without
guidelines. After the introduction of guidelines, this difference increased to 43 percentage
points (OR = 8.3, 95% CI = 1.8-INF; adjusted p = 0.3, one-tailed). Similarly, there
was no difference in the use of validation by reference to the antibody supplier before
the introduction of guidelines. However, after guidelines had been installed, there was
a difference of 27 percentage points (OR = INF, 95% CI = 1.34-INF; adjusted p = 1,
one-tailed) between journals with and without guidelines. It is notable that validation by
reference to information provided in an online antibody database is not used at all.
Change in type of validation carried out by authors of paper
If an antibody was experimentally validated by the article’s authors, we further specified
what type of validation was carried out. Figure 8 and Tables S8 and S9 show an overview
of the change in reported validation types. Figure 8 contains methods that are mostly
used to validate antibodies explicitly. Other types of (often more implicit) validation,
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Figure 7 Change in percentage of validated articles reporting different types of validation before
(2003) and after (2017) the journals with guidelines implemented antibody reporting guidelines.
Sample size (identical for all types of validation unless stated otherwise): with guidelines 2003 n = 23,
2017 n= 27; without guidelines 2003 n= 16, 2017 n= 16; exceptions: reference validation literature with
guidelines 2003 n = 22; reference validation supplier with guidelines 2017 n = 26. P-values (one-tailed)
were determined with Fisher’s exact test and adjusted using the Holm-Bonferroni correction.
Full-size DOI: 10.7717/peerj.9300/fig-7
such as positive and negative control, were also registered but not taken into account for
comparisons because of low interrater reliability.
Examples of validation from the evaluated articles:
• Pre-adsorption. ‘‘In control experiments, primary antibody was pre-adsorbed with rat
ANP (Bachem-Peninsula Laboratories; 1 µM overnight at 4 ◦C) prior to incubation with
tissue sections to assess the degree of non-specific staining. Under these conditions, low
levels of background staining were observed in cortex’’ (Wiggins, Shen & Gundlach, 2003).
• Spatial localization. ‘‘(. . . ) a polyclonal antisera against rat ANP were used in an
attempt to visualize ANP-like-IR in the cerebral cortex and to determine the effect of CSD
on its level and cellular distribution. Consistent with previous reports, ANP-like-IR was
consistently detected in subcortical regions, with a high density of nerve-fibre staining
found throughout areas such as the bed nucleus of the stria terminalis (...), the preoptic
hypothalamus, areas of the amygdala and in the paraventricular thalamic nucleus (see
Kawata et al., 1985, Skofitsch et al., 1985)’’ (Wiggins, Shen & Gundlach, 2003).
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Figure 8 Change in percentage of validated articles reporting different types of validation before
(2003) and after (2017) the journals with guidelines implemented antibody reporting guidelines.
Sample size (identical for all types of validation): with guidelines 2003 n = 20, 2017 n = 23; without
guidelines 2003 n= 15, 2017 n= 15. P-values were determined with Fisher’s exact test and adjusted using
the Holm-Bonferroni correction. All adjusted p-values are 1.
Full-size DOI: 10.7717/peerj.9300/fig-8
• Secondary antibody without primary. ‘‘Additional control incubations with primary
antibody omitted were routinely included and resulted in a lack of specific staining’’
(Wiggins, Shen & Gundlach, 2003).
• Molecular weight in western blot (and KO). ‘‘The rat monoclonal anti - Pcdh10
antibody (MABT20 clone 5G10, Millipore, Billerica, MA, USA) produced a single band
of 137 kDa in the P0 mouse cerebellum and whole brain in our western blot. The band
disappeared completely in samples from Pcdh10 - KO mice (OL - KO homozygotes)’’
(Vibulyaseck et al., 2017).
Before the introduction of guidelines, all types of validation were used more often in
journals without guidelines. However, after the introduction of guidelines, the use of these
validation methods decreased in these journals without guidelines while there was a slight,
but nonsignificant, increase of their use in the journals with guidelines. This means that the
differences in the types of validation that were mostly used increased between journals with
guidelines and similar journals without guidelines. After the introduction of guidelines,
there was a difference of 10 percentage points in the use of pre-adsorption (OR = 2.87,
95% CI = 0.33-INF; adjusted p = 1, one-tailed), 23 percentage points in the use of spatial
localization (OR= 5.9, 95% CI= 0.80-INF; adjusted p-value=1, one-tailed), 32 percentage
points in the use of a secondary antibody without a primary one (OR = 8.6, 95% CI =
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1.22-INF; adjusted p = 1, one-tailed), and 10 percentage points in the use of molecular
weight in western blot (OR= 1.73, 95%CI= 0.39-INF; adjusted p= 1, one-tailed) between
similar journals.
Interestingly, there is a difference in how often these validation types are used in the two
journals that introduced guidelines. In the journal Nature, the methods pre-adsorption
and spatial localization were not used at all before and after the introduction of guidelines.
The small increase in reporting of spatial localization is thus solely caused by its use in the
journal JCN.
DISCUSSION
These results suggest that journal guidelines might have some positive influences on
antibody validation reporting. For example, this is suggested by the large difference in the
percentage of articles reporting validation information of all primary antibodies between
journals with and without guidelines after the introduction of these guidelines. However, it
is notable that in most of our analyses a difference in reporting was already present between
the four journals before the introduction of guidelines. This could suggest that the journal
itself (e.g., its editorial attention to validation, or earlier publications about validation),
regardless of the presence of reporting guidelines, already has an influence on antibody
validation reporting. Another explanation might be that there is a difference in validation
practices and journal selection between research areas or groups.
Moreover, our results provide some insight in how journal guidelines might work.
This can be illustrated by comparing the increase in reporting of validation information
with identification information of all primary antibodies. On average, the reporting
of identification information improved by 58 percentage points, while the reporting
of validation information only improved by 23 percentage points in journals that
introduced guidelines. This suggest that the introduction of antibody reporting guidelines
particularly affected aspects of antibody reporting that are relatively easy to change.
Adding identification information for each antibody used in your publication, such
as catalogue numbers, is easier than providing evidence of actual validation. From an
editorial perspective, the provision of identity information such as catalogue numbers
is also easier to check. At least for some of the articles, researchers seem to have opted
for the easier solutions to comply with antibody guidelines by providing readily available
information.
A similar indication for solutions that choose the ‘path of least resistance’ to comply
with guidelines, can be found in the use of third-party validation information. Once
again, this information is relatively easy to include in a paper with a simple reference and
requires no extra experimental work. Our results show that validation by reference to the
literature increased by 24 percentage points in journals that introduced guidelines, while
this percentage decreased in journals without guidelines. Likewise, validation by reference
to the antibody supplier’s information increased by 27 percentage points in journals with
guidelines, while this method was never used in journals without guidelines. These results
are not significant, but the odds ratios seem to suggest (especially in the case of reference
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to supplier’s information) that these validation practices merit further investigation. More
research assessing how researchers regard journal guidelines, how these guidelines affect
their practices, and a replication of this study with a larger sample size is recommended.
Because the guidelines mostly seem to influence aspects of antibody reporting that are
relatively easy to provide, we concluded that the effects of journal guidelines on antibody
reporting are limited. This limited effect of journal guidelines is consistent with findings
in similar research on journals’ measures to improve reporting about research resources.
A recent evaluation of the 2013 Nature life science checklist shows that it improved the
reporting of some items, but also that approximately half of the compliant articles did not
actually use the tools recommended by the checklist (Han et al., 2017). Another evaluation
of theNature checklist showed improvements in transparency of reported information, but
much more modest improvements in experimental design. Furthermore, the study found
that the checklist did not improve antibody reporting (NPQIP Collaborative group, 2019).
However, with regard to antibody identifiability, our results are more optimistic than
previous studies. Vasilevsky et al. found no relationship between reporting guidelines and
identifiability of resource materials in biomedical research. Identifiability of resources was
actually higher in journals with no or loose guidelines than in journals with strict guidelines.
Antibody identifiability in the Journal of Comparative Neurology was only slightly higher
than average across all journals (Vasilevsky et al., 2013). While our results point towards
some improvements, it is clear that journal guidelines are not a definitive solution to fix
validation and misidentification problems.
Much seems to depend on how journal guidelines are implemented. Mere symbolic
support for guidelines in editorial instructions may not be enough to improve reporting
practices. Baker et al. found that the endorsement of the ARRIVE (Animal Research:
Reporting of In Vivo Experiments) guidelines by journals had little to no impact the
reporting of animal studies in these journals (Baker et al., 2014). Hair et al. (2019) found
that even requiring authors to complete an ARRIVE checklist after submission of their
manuscript did not improve compliance. In another study of journal guidelines regarding
RRIDs, compliance was the lowest when the journals only provided author instructions.
Compliance became higher when authors received mailed instructions, and it became very
high when editorial staff assisted authors with their RRIDs (Bandrowski et al., 2016). These
results suggest that journal guidelines may have a beneficial effect, but that they require
additional measures to make them effective.
Another interesting observation from our study is that, in contrast to the reporting of
antibody validation, the reporting of information on the identity of all primary antibodies
increased in all four journals between 2003 and 2017. Moreover, this percentage increased
significantly by 37 percentage points in the total sample of all four journals combined.
Although the improvement was larger in journals that introduced guidelines, it is likely
that this improvement is at least partly caused by a growing awareness of antibody
problems. That this growing awareness only seems to have an effect on improving antibody
identification reporting and not on antibody validation reporting might be due to the
current attention for reproducibility in science. Although antibody validity is important
for the overall validity of research, detailed reporting of which antibodies were used is
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important to ensure reproducibility. However, as we have argued, reproducible research is
not necessarily valid research. We would therefore urge not to forget the validity question
in the replication crisis debate. Furthermore, it would be interesting to study researchers’
motivation for this change in reporting behaviour to see whether and how it relates to the
reproducibility crisis.
Limitations
Our study has several noteworthy limitations. As an exploratory study, our study was not
pre-registered, which we would recommend for possible future confirmatory replications
of our work. Furthermore, the labour-intensive nature of scrutinising publications for
validation information means our sample and interrater testing are limited. Together with
a conservative statistics test (Fisher’s exact), this might have increased our Type II error.
Having a low power can have several consequences for the reliability of results, such as an
overestimation of the effect size. Readers of our study should be cautious of this limitation
while interpreting our results.
In addition, coding of articles inevitably implies some level of arbitrary convention and
interpretation, for example as we decided to code on the level of articles and not individual
antibodies. No distinction was made between implicit and explicit validation, giving the
researchers the benefit of the doubt with respect to their validation efforts, which may
overestimate the beneficial effect of guidelines and how often certain validation methods
are used. The room for interpretation about whether specific forms of experimental
validation were actually used, is also illustrated by the lower agreement between raters
in this respect. This again means that our results should be regarded with caution and a
replication of this study with a larger sample size and multiple assessors is recommended.
Because of these limitations, we tried to be as open as possible about the decisions we made
during the coding process, by illustrating these choices with examples from the evaluated
articles in this manuscript, and by providing an elaborate explanation of our choices in the
coding table.
Last, our pseudo-experimental research design has some limitations. Because of the
substantial time period from which we took our samples (2003 and 2017), the time
between the intervention of implementing the guidelines and the measurement of changed
behaviour is stretched. We chose this approach because of the implementation of the
guidelines by the two journals at different times. However, another way to approach
this could be by sampling over time, for example by using interrupted time series
analysis. Moreover, the quasi-experimental design makes the effect of journal guideline
introduction hard to isolate from wider influences, such as a growing awareness of the
urgency of antibody validation, or the growing knowledge stored in databases such as the
Antibodyregistry. Fortunately, our results do show signs of an overall growing awareness of
antibody problems, since the reporting of antibody identification information significantly
improved in the entire sample.
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CONCLUSIONS
This study suggests that the implementation of antibody reporting guidelines by a journal
might have some positive influences on the reporting of antibody validation information,
as we hypothesized. The percentage of validated antibodies per article, the percentage
of articles which reported validation and identification of all primary antibodies, and
different types of validation all increased in journals with guidelines after the introduction
of these guidelines. However, improvements were particularly visible for forms of antibody
information that are relatively easy to provide, such as providing complete identification
information. Strictly speaking, such information supports the reliability of antibodies, and
it is conceivable that securely identified and previously validated antibodies can be used
reliably in identical applications. Nevertheless, improvements of more robust experimental
validation were modest, at best. Combined with the results of previous studies on journal
guidelines, this suggests that the effect of journal antibody guidelines by themselves may
be limited and may require additional measures to ensure effective implementation.
In light of the quasi-experimental and exploratory nature of our study, we need to be
careful with drawing these conclusions. Other factors, such as a general shift in research
practices, a change in publication behavior, a preference for publishing in a journal that
adheres to the values of a researcher, or changed editorial practices might also play a role.
More research would therefore be needed to study how researchers make decisions with
regard to antibody validation and how they adjust their research practices in response to
changing journal guidelines.
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